Kappa/Lambda Light-chain Typing in Alzheimer's Disease

dc.authoridŞahin, Şevki/0000-0003-2016-9965en_US
dc.authoridSerteser, Mustafa/0000-0001-7868-7613en_US
dc.authoridakgun, emel/0000-0002-2750-6939en_US
dc.authoridSerdar, Muhittin/0000-0002-3014-748Xen_US
dc.authoridaksungar, fehime benli/0000-0002-7954-7177en_US
dc.authoridKOCA, SEBILE/0000-0003-0945-057Xen_US
dc.authoridKarşıdağ, Sibel/0000-0002-2887-9235en_US
dc.contributor.authorKaya, Zelal Zuhal
dc.contributor.authorTuzuner, Mete Bora
dc.contributor.authorŞahin, Betul
dc.contributor.authorAkgün, Emel
dc.contributor.authorAksungar, Fehime
dc.contributor.authorKoca, Sebile
dc.contributor.authorSerdar, Muhittin
dc.date.accessioned2024-07-12T21:37:51Z
dc.date.available2024-07-12T21:37:51Z
dc.date.issued2022en_US
dc.department[Belirlenecek]en_US
dc.description.abstractBackground: Alzheimer's disease is a progressive neurodegenerative disorder characterized by memory loss and cognitive impairment. The diagnosis of Alzheimer's disease according to symptomatic events is still a puzzling task. Developing a biomarker-based, low-cost, and high-throughput test, readily applicable in clinical laboratories, dramatically impacts the rapid and reliable detection of the disease. Objective: This study aimed to develop an accurate, sensitive, and reliable screening tool for diagnosing Alzheimer's disease, which can significantly reduce the cost and time of existing methods. Methods: We have employed a MALDI-TOF-MS-based methodology combined with a microaffinity chromatography enrichment approach using affinity capture resins to determine serum kappa (kappa) and lambda (lambda) light chain levels in control and patients with AD. Results: We observed a statistically significant difference in the kappa light chain over lambda light chain (kappa LC/lambda LC) ratios between patients with AD and controls (mean difference -0,409; % 95 CI: -0.547 to -0.269; p<0.001). Our method demonstrated higher sensitivity (100.00%) and specificity (71.43%) for discrimination between AD and controls. Conclusion: We have developed a high-throughput screening test with a novel sample enrichment method for determining kappa LC/kappa LC ratios associated with AD diagnosis. Following further validation, we believe our test has the potential for clinical laboratories.en_US
dc.description.sponsorshipAcibadem Labmed Laboratories in Turkey; Scientific and Technological Research Council of Turkey (TUBITAK-Grant) [118C082]en_US
dc.description.sponsorshipThis research was funded by Acibadem Labmed Laboratories in Turkey and supported by the 2244 Industrial Ph.D. program provided by The Scientific and Technological Research Council of Turkey (TUBITAK-Grant#118C082).en_US
dc.identifier.doi10.2174/1567205019666220131101334
dc.identifier.endpage93en_US
dc.identifier.issn1567-2050
dc.identifier.issn1875-5828
dc.identifier.issue1en_US
dc.identifier.pmid35100957en_US
dc.identifier.scopus2-s2.0-85125725716en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage84en_US
dc.identifier.urihttps://doi.org/10.2174/1567205019666220131101334
dc.identifier.urihttps://hdl.handle.net/20.500.12415/6965
dc.identifier.volume19en_US
dc.identifier.wosWOS:000826095800008en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherBentham Science Publ Ltden_US
dc.relation.ispartofCurrent Alzheimer Researchen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.snmzKY04307
dc.subjectAlzheimer's Diseaseen_US
dc.subjectMaldi-Tof-Msen_US
dc.subjectScreening Toolen_US
dc.subjectMicroaffinity Chromatographyen_US
dc.subjectAffinity Capture Resinsen_US
dc.subjectKappa Light Chainen_US
dc.subjectRatioen_US
dc.subjectLambda Light Chain Ratioen_US
dc.titleKappa/Lambda Light-chain Typing in Alzheimer's Diseaseen_US
dc.typeArticle
dspace.entity.typePublication

Dosyalar